Intervention effects of rutaecarpine in type 2 diabetic obese rats

Xu-qiang NIE,Lin-hua YU,Huai-hong CHEN,Tong-feng ZHAO,Ka BIAN
2010-01-01
Abstract:Aim: To estimate the effect of rutaecarpine (Rut) on type 2 diabetic obese rats. Methods: The type 2 diabetic obese rat model (T2DM) was generated with intravenous injection of streptozotocin (30 mg· kg -1) and high-fat diet. The rats then were divided into 3 groups: rutaecarpine (Rut) -treated; metformin (Met; positive control)-treated; and control null-treated. 7 weeks after treatment, the changes of fasting blood glucose (FBG), fasting lipid profile including total cholesterol (TC), triglyceride (TG), low density lipoproteincholesterol (LDL-C) and high density lipoprotein-cholesterol(HDL-C) were observed. In addition, the pathological changes of kidney, liver and pancreas were examined. Results: Rut treatment significantly decreased TC, TG, and LDL-C (P < 0.05) and increased HDL-C (P < 0.05) compared with T2DM non-treated group. The herb element also inhibited the levels of C-reactive protein (CRP; P < 0.05). Rut improved pathological changes in kidney, liver, and pancreas of type 2 diabetic obese rats. But blood glucose levels was not statistically affected by Rut while compared with the Met group. Conclusions: Rutaecarpine can benefit blood lipid profile, mitigate inflammation, and improve kidney, liver, pancreas pathologic status of type 2 diabetic obese rats. The further evaluation of rutaecarpine as a potential agent on diabetic metabolic syndrome is suggested.
What problem does this paper attempt to address?